Redistribution of platelet membrane glycoprotein iv and release of intracellular α-granule thrombospondin in patients with chronic myelogenous leukemia

Abstract

The redistribution of platelet membrane glycoprotein IV (GPIV) and the release of intracellular α-granule thrombospondin (TSP) were examined and the inhibition of β-thromboglobulin (β-TG) and platelet factor 4 (PF4) in patients with chronic myelogenous leukemia (CML) was observed and quantitation of β-TG and PF4 in sera was conducted. GPIV in inactive platelet from CML was 36080± 17010 molecules/platelet as compared with 13190±4810 from the controls (P< 0.01). No abnormality was found in the distribution of platelet membrane GPI_b and GPII_b/III,(P> 0.05). The GPIV redistribution on active platelet membrane induced thrombin (IU/ml) from CML and healthy donors was 44320 ±32310 and 22800± 12700 molecules/platelet respectively (P< 0.01). The difference in the release of intracellular α-granule TSP between CML and the control group was not found (P> 0.05). There was no direct correlation between GPIV expression and TSP binding after platelet activation. The high levels of β-TG and PF4 in sera inhibited release of intracellular α-granule TSPin vitro. These results indicate that the abnormality of platelet membrane GPIV is a common marker in CML, therefore the specific increase of platelet GPIV in patients with CML may be a useful tool for the diagnosis and monitoring of the platelet dysfunction. The release of internal TSP pools is hindered by either β-TG or PF4 in sera.

Keywords

chronic myelogenous leukemia / platelet membrane / glycoprotein IV / thrombospondin

References

[1] WcGregorJ L, CatimelB, ParmentierS, et al.. Rapid purification and partial characterization of human platelet glycoprotein III_b: interaction with thrombospondin and its role in platelet aggregation. J Biol Chem, 1989, 264: 501-501

[2] ThibertV, BellucciS, EdelmanL, et al.. Quantitation of platelet glycoprotein IV (CD36) in healthy subjects and in patient with essential thrombocythemia using an immunocapture assay. Thrombosis and Haemostasis, 1992, 68: 600-600

[3] LegrandC, DubernardV, KiefferN, et al.. Use of a monoclonal antibody to measure the surface expression of thrombospondin following platelet activation. Eur J Biochem, 1988, 171: 393-393

[4] c-myc c-sis. 1995,16:122

[5] BeisoP, PidardD, FournierD, et al.. Studies on the interaction of platelet glycoprotein I_b/I_a and glycoprotein IV with fibrinogen and thrombospondin: A new immunochemical approach. Biochim Biophys Acta, 1990, 1033: 7-7

[6] ClezardinP, McGregorJ L, DechavanneM, et al.. Platelet membrane glycoprotein abnormalitities in patient with myeloproliferative disorders and secondary thrombocytosis. Bri J Hacmatol, 1985, 60: 331-331

[7] ThibertV, BellucciS.Cristofari M, et al.. Increased platelet CD36 constitutes a common marker in myeloproliferation disorders. Bri J Haematol, 1995, 91: 618-618

[8] BergerG, CaenJ P, BernndtM C, et al.. Ultrastructural demonstration of CD36 in the α-granule membrane of human platelet and megakaryocytes. Blood, 1993, 82: 3034-3034

[9] HanZ C, SensebeL, AbgrallJF, et al.. Platelet factor 4 inhibits human megakaryocytopoiesis in vitro. Blood, 1990, 75: 1234-1234

[10] AbgrallJ F, HanZ C, SensebeL, et al.. Inhibitory affect of highly purified human β-thromboglobulinin vitro human megakaryocyte colony formation. Exp Hematol, 1991, 19: 202-202